STOCK TITAN

CDMOP - CDMOP STOCK NEWS

Welcome to our dedicated page for CDMOP news (Ticker: CDMOP), a resource for investors and traders seeking the latest updates and insights on CDMOP stock.

Avid Bioservices, Inc. (symbol: CDMOP) is a dedicated contract development and manufacturing organization (CDMO) focused on biologics. With a state-of-the-art facility and a team of experts, they provide services from cell line development to commercial manufacturing. Avid Bioservices has a strong track record of successful partnerships, cutting-edge technology, and a commitment to quality and compliance.
Rhea-AI Summary

Avid Bioservices (NASDAQ: CDMO) has initiated mailing definitive proxy materials to stockholders regarding its pending transaction with GHO Capital Partners and Ampersand Capital Partners. The deal offers $12.50 per share in cash, representing a $1.1 billion enterprise value and a 13.8% premium to the last trading price before announcement.

The Special Meeting to vote on the transaction is scheduled for January 30, 2025. The Board unanimously recommends stockholders vote 'FOR' the transaction, highlighting three key benefits: immediate cash value, a robust value-maximizing process, and de-risking of the company's standalone future. The deal followed a comprehensive process involving outreach to 24 potential buyers, resulting in a 19% price improvement from the initial unsolicited offer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Avid Bioservices (NASDAQ: CDMO) reported financial results for Q2 FY2025 ended October 31, 2024. Revenue increased 32% to $33.5 million, while backlog grew 11% to $220 million. Despite revenue growth, the company recorded a gross loss of $2.0 million and a net loss of $17.4 million ($0.27 per share).

The company announced its acquisition by GHO Capital Partners and Ampersand Capital Partners in an all-cash transaction valued at $1.1 billion. Shareholders will receive $12.50 per share, representing a 13.8% premium to the closing price on November 6, 2024. The transaction is expected to close in Q1 2025, after which Avid will become private.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Avid Bioservices (NASDAQ: CDMO) has announced a definitive merger agreement to be acquired by GHO Capital Partners and Ampersand Capital Partners in an all-cash transaction valued at $1.1 billion. Shareholders will receive $12.50 per share, representing a 13.8% premium to Avid's closing price on November 6, 2024. The transaction equates to a 6.3x multiple to consensus FY2025E revenue. The deal, unanimously approved by Avid's Board, is expected to close in Q1 2025, subject to stockholder and regulatory approvals. Post-acquisition, Avid will become private while maintaining its name and brand.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

Avid Bioservices (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization, has announced its participation in the upcoming Craig-Hallum Bioprocessing Conference. The virtual event is scheduled for September 19, 2024.

Key highlights:

  • President and CEO Nick Green and VP of Process Development Pramthesh Patel, Ph.D., will be featured speakers
  • The fireside chat is set for 2:45 p.m. Eastern on the conference day
  • A webcast replay will be available on Avid's investor website after the event

This participation underscores Avid Bioservices' commitment to engaging with industry stakeholders and showcasing its expertise in biologics manufacturing and development services.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

Avid Bioservices (NASDAQ: CDMO) reported financial results for Q1 FY2025 ended July 31, 2024. Key highlights include:

- Revenue of $40.2 million, up 6% year-over-year
- Net new business signings of $66 million
- Backlog increased to $219 million, up 16% from last year
- Gross profit of $5.7 million (14% margin)
- Net loss of $5.5 million or $0.09 per share
- Cash and equivalents of $33.4 million

The company maintained its FY2025 revenue guidance of $160-$168 million. Avid's CEO Nick Green highlighted strong momentum, improved margins, and diverse new business signings, including early-phase programs and late-stage projects advancing toward commercialization.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Avid Bioservices (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization, has announced it will report financial results for the first quarter of fiscal year 2025 on September 9, 2024, after market close. The company will also host a webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time) on the same day. During the webcast, Avid's senior management will discuss the financial results and review recent corporate developments. Investors and interested parties can access the live or archived webcast through the company's investor relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
Rhea-AI Summary

Avid Bioservices (NASDAQ: CDMO) reported fourth quarter revenue of $43 million, the highest in the company's history, and full-year fiscal 2024 revenue of $139.9 million, a 6% decrease from the previous year. Despite a strong quarter, the full year was impacted by fewer manufacturing runs and changes in estimated variable consideration. The company signed $30 million in new business, resulting in a backlog of $193 million. For fiscal 2025, Avid projects revenue between $160 million and $168 million. Gross profit for Q4 was $5.5 million (13% margin), down from $8.4 million (21% margin) in Q4 2023. Full-year gross profit was $7.3 million (5% margin), down from $31.5 million (21% margin) last year. The net loss for Q4 was $123.1 million or $1.94 per share, primarily due to a $118.5 million income tax expense. The net loss for the full year was $140.8 million or $2.23 per share, compared to net income of $0.3 million last year. Cash and cash equivalents stood at $38.1 million as of April 30, 2024. New facilities are fully operational, increasing the annual revenue-generating capacity to over $400 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Avid Bioservices (NASDAQ: CDMO) will announce its financial results for the quarter and fiscal year ended April 30, 2024, following market close on July 2, 2024. A webcast hosted by senior management will take place at 1:30 PM PT (4:30 PM ET) to discuss the financial outcomes and recent corporate developments. The webcast can be accessed live or via archive on the company’s investor relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
Rhea-AI Summary

Avid Bioservices (NASDAQ: CDMO) announced on May 23, 2024, that it has earned a Committed Badge from EcoVadis, a leading provider of business sustainability ratings.

The company scored 56, placing it in the 62nd percentile globally. This recognition covers four core themes: Environment, Labor & Human Rights, Ethics, and Sustainable Procurement.

CEO Nick Green emphasized the company's commitment to ongoing sustainability improvements, recognizing that achieving high sustainability ratings is a continuous process.

EcoVadis evaluates over 125,000 companies worldwide based on international sustainability standards like the UN Global Compact and ISO 26000.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Avid Bioservices, Inc. (NASDAQ: CDMO) will participate in two investor conferences with Nick Green, the president and CEO, as a key speaker. The company aims to enhance patient lives through biologics development and manufacturing services for biotech and pharma firms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences

FAQ

What does Avid Bioservices, Inc. do?

Avid Bioservices is a contract development and manufacturing organization (CDMO) specializing in biologics, offering services from cell line development to commercial manufacturing.

What sets Avid Bioservices apart from other CDMOs?

Avid Bioservices stands out for its state-of-the-art facility, expert team, successful partnerships, cutting-edge technology, and commitment to quality and compliance.

What services does Avid Bioservices provide?

Avid Bioservices offers a range of services including process development, analytical services, clinical and commercial manufacturing, and regulatory support.

Can companies partner with Avid Bioservices for biologic manufacturing?

Yes, Avid Bioservices has a history of successful partnerships with companies looking for reliable and high-quality biologic manufacturing services.

What is the expertise of Avid Bioservices?

Avid Bioservices has a team of experts with extensive experience in biologics manufacturing, ensuring high-quality and efficient services for their clients.

CDMOP

Nasdaq:CDMOP

CDMOP Rankings

CDMOP Stock Data

1.57M
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Tustin